Inventiva’s lanifibranor has been tipped to become a blockbuster in the fatty liver disease non-alcoholic steatohepatitis (NASH) after it became the first drug to hit two regulatory goals in a trial.

Intercept Pharmaceuticals has accused the FDA of moving the goalposts during its review of a potential blockbuster drug for the fatty liver disease known as NASH following a rejection. Intercept’s CEO ...

As the year draws to an end, AFL.com.au has trawled through all 216 games and identified the best 12 from the season. What do ...

Capital Group, the parent of American Funds, recently completed its latest periodic firmwide self-assessment, which will result in personnel changes across its strategy lineup, including American ...

Capital Group, the parent of American Funds, recently completed its latest periodic firmwide self-assessment, which will result in personnel changes across its strategy lineup, including American ...

Given our glowing reviews of the Renault 5, we had high hopes for the bigger, more practical 4 – and our first drive on UK roads shows the car in its very best light. This is still a small, ...